Loading
Life sciences · Interventional Study
ClinicalTrials.gov · October 6, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Interventional Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT05905796). This is a study registration, not published results. Lead sponsor: University of California, San Francisco. Recruitment status: COMPLETED. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 1261 participants (ACTUAL). Conditions: Dementia, Alzheimer Disease. Interventions: OTHER: Brain Health Assessment. Primary outcome measures: New Diagnoses of Dementia (12 Months) , 12 months after index date. Brief summary: The eRADAR Brain Health Study is an embedded, pragmatic clinical trial to determine whether targeted screening for dementia using the eRADAR algorithm increases dementia detection within primary care compared to usual care.